[go: up one dir, main page]

US20200038347A1 - Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same - Google Patents

Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same Download PDF

Info

Publication number
US20200038347A1
US20200038347A1 US16/480,294 US201816480294A US2020038347A1 US 20200038347 A1 US20200038347 A1 US 20200038347A1 US 201816480294 A US201816480294 A US 201816480294A US 2020038347 A1 US2020038347 A1 US 2020038347A1
Authority
US
United States
Prior art keywords
phenyl biguanide
piperidine
pharmaceutical composition
trifluoromethoxy
biguanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/480,294
Other languages
English (en)
Inventor
Jungsik Song
Beom Seok Kim
Sang Jun Ha
Ji Min SON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Immunomet Therapeutics Inc
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Immunomet Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University, Immunomet Therapeutics Inc filed Critical Industry Academic Cooperation Foundation of Yonsei University
Assigned to IMMUNOMET THERAPEUTICS INC., INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY reassignment IMMUNOMET THERAPEUTICS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HA, SANG JUN, KIM, BEOM SEOK, SON, JI MIN, SONG, JUNGSIK
Publication of US20200038347A1 publication Critical patent/US20200038347A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Definitions

  • the present disclosure relates to a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, or combinations thereof, the pharmaceutical composition including a phenylbiguanide derivative compound, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition.
  • T lymphocytes are one type of white blood cells, accounting for about 30% of white blood cells. T lymphocytes can be sub-categorized as naive T lymphocytes, helper T lymphocytes, cytotoxic T lymphocytes, and memory T lymphocytes, and the like. Memory T lymphocytes are cells capable of being rapidly activated after long-term survival when an antigen, which has been recognized thereby, invades again. Secondary immune responses by memory T lymphocytes play an important role in immune response, but memory T lymphocytes may cause disease such as excessive immune response or autoimmune disease.
  • Inflammatory disease is a disease with inflammation manifesting as a major lesion and accompanied by various symptoms such as pain, fever and edema.
  • Autoimmune disease develops when an immune cell attacks organs or tissues of the body, resulting in immune imbalance or loss of resistance to self-antigens.
  • an N1-cyclicamine-N5-substituted phenylbiguanide derivative compound has been known to have anticancer, anti-hyperglycemic and lipid lowering effects (Korean Patent Application Publication No. 10-2013-0019351).
  • the effect of the N1-cyclicamine-N5-substituted phenylbiguanide derivative compound on the immune response was not known.
  • compositions for preventing or treating inflammatory disease, autoimmune disease, or combinations thereof are provided.
  • An aspect provides a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof.
  • R 1 and R 2 form a 3 to 8-membered heterocyclic ring, together with nitrogen connected thereto,
  • n is an integer from 0 to 5
  • R 3 when R 3 is one or more, R 3 may each independently be selected from the group consisting of hydrogen, halogen, hydroxy, a C 1 to C 6 alkyl, a C 1 to C 6 alkoxy, a C 1 to C 6 alkylthio, amino, amide, sulfonamide, nitro, heteroaryl, cyano, sulfonic acid, and sulfamoyl, and
  • R 1 , R 2 , and R 3 may each independently unsubstituted or substituted with at least one substituent selected from the group consisting of halogen, hydroxy, and a C 1 to C 6 alkyl.
  • halogen refers to an atom belonging to Group 7 of the Periodic Table.
  • the halogen atom includes fluorine, chlorine, bromine, iodine, and the like.
  • alkyl refers to a fully saturated branched or unbranched (or linear) hydrocarbon.
  • the alkyl may be a C 1 to C 6 , C 1 to C 5 , C 1 to C 4 , or C 1 to C 3 alkyl group.
  • Non-limiting examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, n-pentyl, isopentyl, neopentyl, iso-amyl, and n-hexyl.
  • alkoxy refers to an alkyl linked to an oxygen atom.
  • the C 1 to C 6 alkoxy group may be, for example, a C 1 to C 6 , C 1 to C 5 , C 1 to C 4 , or C 1 to C 3 alkoxy group.
  • alkylthio refers to alkyl linked to a sulfur atom.
  • the C 1 to C 6 alkylthio group may be, for example, a C 1 to C 6 , C 1 to C 5 , C 1 to C 4 , or C 1 to C 3 alkylthio group.
  • heteroaryl refers to a monocyclic or bicyclic organic compound containing at least one heteroatom selected from the group consisting of N, O, P, and S and carbon as the remaining ring atoms.
  • the heteroaryl group may include, for example, 1 to 5 heteroatom and a 5 to 10-membered ring member. S or N may be oxidized to have various oxidation states.
  • heteroaryl are thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,
  • heterocyclic ring refers to a cyclic hydrocarbon containing at least one heteroatom.
  • the heterocyclic ring may include, for example, a 1 to 5 hetero atoms, and a 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, or 8-membered ring member.
  • the hetero atom may be at least one selected from the group consisting of sulfur, nitrogen, oxygen and boron.
  • substitution refers to a case in which at least one hydrogen atom in an organic compound is substituted with other atomic groups to form a derivative, that is, the other atomic groups are introduced instead of the hydrogen atom to the organic compound, and the term “substituent” refers to the introduced atomic group.
  • R 1 and R 2 may form a 3 to 8-membered heterocyclic ring together with nitrogen linked thereto.
  • the heterocyclic ring may be a 4- to 7-membered nitrogen-containing heterocyclic ring.
  • the heterocyclic ring may be a 5-membered nitrogen-containing heterocyclic ring.
  • the nitrogen may be from 1 to 3 nitrogen atoms.
  • the heterocyclic ring may be, for example, pyrrolidine, azetidine, piperidine, morpholine, piperazine, azepanyl, and aziridine.
  • n may be an integer from 0 to 5. n may be an integer from 0 to 3. n may be 0, 1, 2, 3, 4, or 5.
  • R 3 may each independently be selected from the group consisting of hydrogen, halogen, hydroxy, a C 1 to C 6 alkyl, a C 1 to C 6 alkoxy, a C 1 to C 6 alkylthio, amino, amide, sulfonamide, nitro, heteroaryl, cyano, sulfonic acid, and sulfamoyl.
  • R 3 may each independently be selected from the group consisting of hydrogen, halogen, hydroxy, a C 1 to C 6 alkyl, a C 1 to C 6 alkoxy, and heteroaryl.
  • R 1 , R 2 , and R 3 may each independently unsubstituted or substituted with at least one substituent selected from the group consisting of halogen, hydroxy, and a C 1 to C 6 alkyl.
  • R 3 may be substituted with at least one selected from the group consisting of halogen, hydroxy, and a C 1 to C 6 alkyl.
  • R 3 may be substituted with one, two, or three halogen(s).
  • R 3 may be, for example, a trifluoromethyl group or a trifluoromethoxy group.
  • the compound of Formula 1 may be N1-piperidine-N5-(3-bromo)phenylbiguanide, N1-piperidine-N5-phenyl biguanide; N1-piperidine-N5-(3-methyl)phenyl biguanide; N1-piperidine-N5-(3-ethyl)phenyl biguanide; N1-piperidine-N5-(3-hydroxy)phenyl biguanide; N1-piperidine-N5-(3-hydroxymethyl)phenyl biguanide; N1-piperidine-N5-(3-methoxy)phenyl biguanide; N1-piperidine-N5-(4-fluoro)phenyl biguanide; N1-piperidine-N5-(2-fluoro)phenyl biguanide; N1-piperidine-N5-(3-fluoro)phenyl biguanide; N1-pyrrolidine-N5
  • the compound of Formula 1 may be N1-pyrrolidine-N5-(4-trifluoromethoxy)phenyl biguanide, N1-pyrrolidine-N5-(4-trifluoromethyl)phenyl biguanide, N1-piperidine-N5-(4-fluoro)phenyl biguanide, N1-piperidine-N5-(4-(1H-tetrazole-5-yl))phenyl biguanide, N1-pyrrolidine-N5-(3,4-dichloro)phenyl biguanide, or N1-piperidine-N5-(3,5-dimethoxy)phenyl biguanide.
  • the compound of Formula 1 may be any one of compounds represented by Formulae 2 to 7.
  • stereoisomer refers to compounds that have the same molecular formula and constituting atoms which are linked in the same manner but different spatial arrangement of their atoms.
  • the stereoisomer may be a diasteromer or an enantiomer.
  • the enantiomer refers to an isomer that does not overlap a mirror image thereof like the relation between a right hand and a left hand, and is also called an optical isomer.
  • the enantiomer is categorized as R (Rectus: a clockwise direction) and S (sinister: an anti-clockwise direction), when 4 or more substituents are different from each other at the chiral central carbon.
  • the diastereoisomer refers to a stereoisomer that does not have a mirror-image relationship, and is categorized as a cis isomer and a trans isomer according to the atomic spatial arrangement.
  • derivative refers to a compound obtained by replacing part of the structure of the compound with other atoms or other atomic groups.
  • solvate refers to a compound solvated in an organic or inorganic solvent.
  • the solvate may be, for example, a hydrate.
  • salt of the “pharmaceutically acceptable salt” refers to an addition salt of an inorganic acid salt, organic acid salt, or metal salt of a compound.
  • the pharmaceutically acceptable salt may be a salt that does not cause serious irritation to the organism to which a compound is administered and does not impair the biological activity and properties of the compound.
  • the inorganic acid salt may be hydrochloride, bromate, phosphate, sulfate, or disulfide.
  • the organic acid salt may be a formate, an acetate, a propionate, a lactate, an oxalate, a tartrate, a malate, a maleate, a citrate, a fumarate, a besylate, a camsilate, an edisylate, a trichloroacetic acid, a trifluoroacetate, a benzoate, a gluconate, a methansulfonate, a glycolate, a succinate, a 4-toluenesulfonate, a galacturonate, an embonate, a glutamate, a methansulfonic acid, an ethanesulfonic acid, a benzenesulfonic acid, a p-toluenesulfonic acid, or an aspartate.
  • the metal salt may be a calcium salt, a sodium salt, a magnesium salt, a strontium salt, or
  • inflammation of the “inflammatory disease” refers to one of the biological reactions to harmful stimulants in living tissues, for example, pathogenic microorganisms, damaged cells, stimulants and the like. Inflammation can be caused by a variety of causes, such as infection by microorganisms or injuries, surgery, burns, frostbite, electrical stimulation, and chemicals.
  • the inflammatory disease refers to a disease that involves inflammation as a major lesion.
  • the Inflammatory disease may be, selected from the group consisting of sepsis, gastritis, enteritis, nephritis, hepatitis, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, hypersensitivity colorectal syndrome, inflammatory pain, migraine, headaches, back pain, fibromyalgia, fascial disease, viral infection, bacterial infection, fungal infection, burns, wounds due to surgical or dental surgery, prostaglandin excessive syndrome, atherosclerosis, gout, Hodgkin's disease, pancreatitis, conjunctivitis, ulceris, uveitis, and eczema.
  • COPD chronic obstructive pulmonary disease
  • autoimmune disease refers to a disease in which an immune-function abnormality occurs, resulting in immune cells in the body attacking organs or tissues of the body.
  • the autoimmune disease can be categorized as a disease associated with organ-specific autoantibodies and an organ non-specific (systemic) disease.
  • the autoimmune disease may be selected from the group consisting of hemophagocytic lymphohistiocytosis, systemic lupus erythematosus, Kikuchi disease, vasculitis, adult onset Still's disease, rheumatoid arthritis, inflammatory myositis, Behcet disease, IgG4-related disease, Sjogren syndrome, giant cell arteritis, temporal arteritis, Type 1 diabetes, atopic dermatitis, Crohn's disease, systemic sclerosis, psoriasis, multiple sclerosis, and Graves hyperthyroidism.
  • the compound of Formula 1, and the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof may inhibit the differentiation or proliferation of a memory T cell.
  • the memory T cell may be a central memory T cell (T CM ), or an effector memory T cell (T EM ).
  • the compound of Formula 1, and the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof may promote the differentiation or proliferation of the effector T cell (T EFF ).
  • T CM may express CD127 protein and CD62L protein.
  • T EM may express CD127 protein, but may not express CD62L protein.
  • T EFF may not express CD127 protein and CD62L protein.
  • prevention refers to any action that inhibits the development of, or delays the onset of inflammatory disease, autoimmune disease, or combinations thereof by the administration of the pharmaceutical composition.
  • treatment refers to any action that alleviates or advantageously alters the symptoms of inflammatory disease, autoimmune disease, or combinations thereof by the administration of the pharmaceutical composition.
  • the pharmaceutical composition may include a pharmaceutically acceptable carrier.
  • the carrier is used herein to include an excipient, a diluent, or an adjuvant.
  • the carrier may be, for example, selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, physiological saline, a buffer such as PBS, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • the pharmaceutical composition may include fillers, anticoagulants, lubricants, wetting agents, flavors, emulsifiers, preservatives, or combinations thereof.
  • the pharmaceutical composition may be prepared in any formulation according to methods of the related art.
  • the pharmaceutical composition may be formulated as, for example, an oral dosage form (powder, tablet, capsule, syrup, pill, or granule), or a parenteral formulation (for example, an injection).
  • the pharmaceutical composition may be formulated as a systemic formulation or as a topical formulation.
  • the pharmaceutical composition may further include an immunosuppressive agent.
  • immunosuppressive drug refers to a substance that inhibits immune functions.
  • the immunosuppressive drug may glucocorticoid, a cell proliferation inhibitor, an antibody or antigen-binding fragment, a drug acting on immunophilin, and the like.
  • the cell proliferation inhibitor may be an alkylating agent, an antimetabolite (for example, methotrexate, azathioprine, mercaptopurine, and fluorouracil), or the like.
  • the antibody or antigen-binding fragment may be, for example, an antibody or antigen-binding fragment that binds specifically to a T-cell receptor or a IL-2 receptor.
  • the drug acting on immunophilin may be, for example, ciclosporin, tacrolimus, rapamycin, and everolimus.
  • the immunosuppressive drug may include interferon, opioid, a tumor necrosis factor (TNF) binding protein, mycophenolate, or the like.
  • the immunosuppressive drug may be, for example, rapamycin.
  • the pharmaceutical composition may be a single composition or separate compositions.
  • the pharmaceutical composition may include the compound of Formula 1, or the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof in an effective amount.
  • effective amount refers to an amount sufficient to show the effect of prevention or treatment when administered to a subject in need of such prevention or treatment.
  • the effective amount may be appropriately determined by ordinary skilled in the art according to the subject.
  • the effective amount may depend on the severity of the disease, the age, body weight, health conditions, and gender of the patient, sensitivity to the drug, administration hours, route of administration and rate of excretion of the patient, duration of treatment, a combination with the used composition, or drugs simultaneously used with the composition, and other factors that are known in the medical field.
  • the effective amount may be, based on the amount of the pharmaceutical composition, in the range of about 0.5 ⁇ g to about 2 g, about 1 ⁇ g to about 1 g, about 10 ⁇ g to about 500 mg, about 100 ⁇ g to about 100 mg, or about 1 mg to about 50 mg.
  • the pharmaceutical composition may be administered in a conventional manner via oral, transdermal, subcutaneous, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, topical, or intradermal routes.
  • the dosage of the pharmaceutical composition may be, for example, based on an adult, in the range of about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 10 mg/kg, or about 0.1 mg/kg to about 1 mg/kg.
  • the administration may be performed once a day, multiple times a day, once a week, once every two weeks, once every three weeks, or once every four weeks to once a year.
  • Another aspect provides a method of preventing or treating inflammatory disease, autoimmune disease, or combinations thereof, the method including administering, to a subject, the compound of Formula 1, or the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof.
  • the method includes administering, to a subject, the compound of Formula 1, or the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof.
  • the compound of Formula 1, the stereoisomer, the derivative, the solvate, pharmaceutically acceptable salt, the inflammatory disease, the autoimmune disease, the prevention, and the treatment are the same as described above.
  • the subject may be mammals, for example, humans, cows, horses, pigs, dogs, sheep, goats, or cats.
  • the subject may be suffering from, or at risk of, inflammatory disease, autoimmune disease, or combinations thereof.
  • the method may further include administering an immunosuppressive drug to the subject.
  • the immunosuppressive drug may be administered simultaneously, separately, or sequentially with the compound of Formula 1, or the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof.
  • the administering may be performed via oral or parenteral routes.
  • the administering may be performed via, for example, oral, transdermal, subcutaneous, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, topical, intranasal, intratracheal, or intradermal routes.
  • the pharmaceutical composition may be administered systemically or topically and may be administered alone or in combination with other pharmaceutically active compounds.
  • the dosage of the compound of Formula 1, or the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof may depend on the conditions and body weight of the patient, the severity of the disease, the formulation of the drug, and the administration route and period. However, the dosage may be appropriately determined by a person skilled in the art.
  • the dosage may be, for example, based on an adult, in the range of about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 10 mg/kg, or about 0.1 mg/kg to about 1 mg/kg.
  • the administration may be performed once a day, multiple times a day, once a week, once every two weeks, once every three weeks, or once every four weeks to once a year.
  • the pharmaceutical composition including the compound of Formula 1, or the stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof according to an aspect and the method using the pharmaceutical composition according to another aspect can be used to effectively prevent or treat inflammatory disease, autoimmune disease, or combinations thereof.
  • FIGS. 1A and 1B show graphs of a proliferation ratio of a CD4 T cell (%) and a proliferation ratio of a CD8 T cell (%) with respect to HL-156A, rapamycin, metformin, or a combination thereof, respectively (error bar: 95% confidence interval, Rapa: rapamycin).
  • FIG. 2A shows a graph of the amount of TNF- ⁇ (pg/ml) produced in a THP-1 cell according to the administration of HL-156A, HL-156B, HL-156C, HL-156D, HL-156E, and HL-156F
  • FIG. 2B shows a graph of the amount of TNF- ⁇ ( ⁇ g/ml) produced in MH7A cells according to the administration of HL-156A or HL-156B.
  • FIG. 3 shows a schematic diagram illustrating a process of administering, to a mouse, HL-156A, or a combination of HL-156A and rapamycin.
  • FIG. 4A shows a graph showing results obtained by flow cytometric analysis.
  • FIG. 4B shows a ratio (%) of a CD127+CD62L+ T CM cell, a CD127+CD62L ⁇ T EM cell, and a CD127 ⁇ CD62L ⁇ T EFF cell in PBMC over time after the viral infection.
  • FIG. 4C shows a ratio (%) of a CD127+CD62L+ T CM cell, a CD127+CD62L ⁇ T EM cell, and a CD127 ⁇ CD62L ⁇ T EFF cell in PBMC in T cells of a spleen.
  • FIG. 5 shows a graph of a change in arthritis score over time in a mouse model of collagen-induced arthritis when HL-156A was administered.
  • the spleen was harvested from normal C57BL/6 mice (Orient Bio) and the mixture obtained by adding a RPMI solution containing 2% (v/v) fetal bovine serum (FBS) to the spleen tissues was homogenized by using a 40 ⁇ m strainer.
  • FBS fetal bovine serum
  • T cells were isolated from the homogenized spleen tissue by using CD90.2 magnetic beads (Miltenyi Biotec). Isolated T cells were labeled using CellTraceTM Violet (CTV). Subsequently, labeled T cells were activated for 3 days by using anti-CD3/28 Dynabeads®.
  • HL-156A Hanoi BioPharma Inc.
  • 20 nM rapamycin LC Laboratories
  • 20 nM rapamycin As a negative control, PBS supplemented with 5% (v/v) DMSO was used.
  • 20 nM rapamycin or 2 mM metformin As anoi BioPharma Inc. was used.
  • Activated T cells were immunostained by using allophycocyanin (APC)-labeled anti-CD4 antibody (BD Biosciences) and peridinin chlorophyll protein complex (PerCP)-labeled anti-CD8 antibody (eBioscience). Immunostained T cells were analyzed by flow cytometric analysis to identify the surface molecular phenotype thereof. From the results obtained by flow cytometric analysis, the proliferation ratio (%) of the T cell with respect to a material treated on the T cell was calculated, and the proliferation ratio (%) of CD4 T cell and the proliferation ratio (%) of CD8 T cell with respect to a compound are shown in FIGS. 1A and 1B , respectively.
  • APC allophycocyanin
  • PerCP peridinin chlorophyll protein complex
  • HL-156A significantly inhibited the proliferation of CD4 T cell and CD8 T cell in proportion to the concentration.
  • the combination of HL-156A and rapamycin inhibited the proliferation of T cells compared with when HL-156A and rapamycin were used separately. This result identifies that the combination of HL-156A and rapamycin has a synergistic effect.
  • the human THP-1 cell line (ATCC) was prepared and cultured at a temperature of 37° C. and under 5% CO 2 .
  • THP-1 cells were inoculated onto a 96-well plate at the density of 1 ⁇ 10 5 , and HL-156A, HL-156B, HL-156C, HL-156D, HL-156E, and HL-156F (all produced by Hanoi BioPharma Inc.) were added at the concentration of 1 ⁇ M or 10 ⁇ M to the cell culture solution. Thereafter, 25 ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) was added to the cell culture solution, and cells were cultured for 24 hours, and then, lipopolysaccharide (LPS) was added thereto to induce an immune response of THP-1 cell. As a negative control, a group in which LPS was not added or a group in which LPS was added but no drug was added, were used.
  • PMA phorbol 12-myristate 13-acetate
  • LPS lipopolysaccharide
  • THP-1 cells were cultured for 24 hours, and then, the amount of tumor necrosis factor-alpha (TNF- ⁇ ) in the culture solution by using TNF ELISA kit (Invitrogen) was measured.
  • the amount (pg/ml) of TNF- ⁇ produced in THP-1 cells according to the administered drug is shown in FIG. 2A and Table 1.
  • HL-156A, HL-156B, HL-156E, and HL-156F inhibited the production of TNF- ⁇ in cells. Since TNF- ⁇ is a cytokine associated with systemic inflammation and acts to regulate immune cells, it was confirmed that HL-156 compound could inhibit the inflammatory response.
  • Human synoviocyte cell line MH7A (provided by Prof. Kim Wan-wook of clergy University) was prepared and cultured at a temperature of 37° C. and under 5% CO 2 .
  • the prepared MH7A cells were inoculated onto a 96-well plate at the density of 3 ⁇ 10 4 cells, and lipopolysaccharide (LPS) was added thereto to induce the immune response of MH7A cells. Then, HL-156A or HL-156B was added at a concentration of 0.1 ⁇ M, 1 ⁇ M, or 10 ⁇ M to the cell culture solution. As a negative control, a group in which LPS was used but no drug was used, was used.
  • LPS lipopolysaccharide
  • TNF- ⁇ in the culture solution was measured by using a TNF- ⁇ ELISA kit (Peprotach).
  • Table 2 shows the amount of TNF- ⁇ according to the administration of drug
  • FIG. 2B shows a graph of the amount of TNF- ⁇ ( ⁇ g/ml) produced in MH7A cells when HL-156A or HL-156B was administered.
  • HL-156A and HL-156B inhibited the production of TNF- ⁇ in a concentration-dependent manner in the cells. Therefore, it was confirmed that HL-156 compound can inhibit inflammatory reaction or prevent or treat arthritis in the synovial membrane cells.
  • lymphocytic choriomeningitis virus LCMV
  • LCMV lymphocytic choriomeningitis virus
  • the mouse was administered with HL-156A every other day at a dosage of 5 mg/kg body weight or 20 mg/kg body weight. Also, in a group administered with rapamycin, rapamycin was administered to the mouse at a dosage of 75 ⁇ g/kg body weight on a daily basis. In a group administered with HL-156A and rapamycin, the mouse was administered with HL-156A at a dosage of 5 mg/kg body weight once every two days, and administered with rapamycin at a dosage of 75 ⁇ g/kg body weight daily. As a negative control, PBS supplemented with 5% (v/v) DMSO was used.
  • FIG. 3 shows a schematic diagram illustrating a process of administering, to a mouse, HL-156A, or a combination of HL-156A and rapamycin.
  • isolated GP33+ CD8 T cells were immunostained by using phycoerythrin (PE)-labeled anti-CD127 antibody (eBioscience) and fluorescein isothiocyanate (FITC)-labeled anti-CD62L antibody (BioLegend), and the surface molecular phenotype of T cells was analyzed by flow cytometry. From results obtained by flow cytometric analysis, the change in differentiation of virus-specific CD8+ T cell over time after the viral infection when HL-156A, or the combination of HL-156A and rapamycin was administered, was confirmed, and shown in FIG. 4A .
  • PE phycoerythrin
  • FITC fluorescein isothiocyanate
  • the ratio of central memory T cell (T CM ) expressing CD127 and CD62L (CD127+CD62L+), effector memory T cell (T EM ) expressing CD127 and not expressing CD62L (CD127+CD62L ⁇ ), and effector T cell (T EFF ) not expressing CD127 and CD62L (CD127 ⁇ CD62L ⁇ ) was calculated.
  • the ratio (%) of CD127+CD62L+ T CM cell, CD127+CD62L ⁇ T EM cell, and CD127 ⁇ CD62L ⁇ T EFF cell in PBMC over time after the viral infection, when HL-156A, or the combination of HL-156A and rapamycin was administered, is shown in FIG. 4B .
  • FIG. 4C shows the ratio (%) of CD127+CD62L+ T CM cell, CD127+CD62L ⁇ T EM cell, and CD127 ⁇ CD62L ⁇ T EFF cell in PBMCs in T cells of spleen on day 31.
  • HL-156A inhibited the differentiation of T CM cells and T EM cells in PBMCs and promoted the proliferation of T EFF cells in PBMCs.
  • rapamycin promoted differentiation of T CM cells and T EM cells in PBMCs and inhibited the proliferation of T EFF cells in PBMCs.
  • HL-156A inhibits the differentiation or production of memory T cells and promotes the proliferation of effector T cells. Therefore, it was confirmed that HL-156A has an effect capable of treating and preventing T cell-associated disease, for example, Inflammatory disease or autoimmune disease.
  • Bovine Type II collagen was dissolved in complete freund's adjuvant (CFA) containing 250 ⁇ g per mouse of heat-sterilized Mycobacterium tuberculosis H37Ra (BD Sciences) to prepare a collagen solution.
  • CFA complete freund's adjuvant
  • DBA/1 mouse was immunized by intradermally injecting 100 g per mouse of the prepared collagen thereinto.
  • bovine Type II collagen dissolved in incomplete freund's adjuvant (IFA) was injected subcutaneously into the tail of a mouse in an amount of 100 ⁇ g to boost the immune system.
  • the arthritis score of mice was measured using the following criteria:
  • Grade 0 swelling or erythema
  • Grade 1 mild swelling and erythema, inflammation of the toes
  • Grade 2 moderate swelling and erythema confined to the distal to mid-limbs
  • Grade 3 extended to the ankle, clear swelling and erythema
  • Grade 4 Severe swelling, erythema, and joint stiffness of ankle, foot, and toes.
  • a score of 0 to 4 was assigned to each leg, and a maximum of 16 points of arthritis scores were assigned to each mouse.
  • mice with an average arthritis score of 8 were randomly selected.
  • the HL-156A compound was diluted in PBS and administered to the selected mice intraperitoneally once every two days with 60 mg/kg body weight of HL-156A compound. Thereafter, the arthritis score of the mouse was measured, and the change in arthritis score over time is shown in FIG. 5 (*: p ⁇ 0.05).
  • the HL-156A compound decreased the arthritis score over time. Therefore, it was confirmed that HL-156A compound has the effect of treating and preventing arthritis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US16/480,294 2017-01-24 2018-01-23 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same Abandoned US20200038347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170011143 2017-01-24
KR10-2017-0011143 2017-01-24
PCT/KR2018/000989 WO2018139828A1 (fr) 2017-01-24 2018-01-23 Compositions pharmaceutiques pour la prévention ou le traitement d'une maladie inflammatoire, d'une maladie auto-immune, ou d'une combinaison de celles-ci, et leur procédé d'utilisation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/000989 A-371-Of-International WO2018139828A1 (fr) 2017-01-24 2018-01-23 Compositions pharmaceutiques pour la prévention ou le traitement d'une maladie inflammatoire, d'une maladie auto-immune, ou d'une combinaison de celles-ci, et leur procédé d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/126,478 Continuation US11826324B2 (en) 2017-01-24 2020-12-18 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same

Publications (1)

Publication Number Publication Date
US20200038347A1 true US20200038347A1 (en) 2020-02-06

Family

ID=62978616

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/480,294 Abandoned US20200038347A1 (en) 2017-01-24 2018-01-23 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same
US17/126,478 Active 2038-04-04 US11826324B2 (en) 2017-01-24 2020-12-18 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/126,478 Active 2038-04-04 US11826324B2 (en) 2017-01-24 2020-12-18 Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same

Country Status (3)

Country Link
US (2) US20200038347A1 (fr)
KR (2) KR20180087189A (fr)
WO (1) WO2018139828A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114681438A (zh) * 2022-05-17 2022-07-01 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102465432B1 (ko) 2021-01-14 2022-11-09 계명대학교 산학협력단 크리소파놀을 유효성분으로 포함하는 t 세포의 과활성 억제용 조성물, 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9321742B2 (en) * 2011-08-08 2016-04-26 Immunomet Therapeutics Inc. N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
WO2013022278A2 (fr) * 2011-08-08 2013-02-14 Hanall Biopharma Co., Ltd. Dérivés de phényl biguanide à substitution n1-amine cyclique-n5, procédés de préparation associés et composition pharmaceutique les comprenant
KR101994145B1 (ko) * 2013-01-28 2019-07-01 한올바이오파마주식회사 Ν１-고리아민-ν５-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 시차증후군의 예방 또는 치료용 약학 조성물
WO2014123364A1 (fr) * 2013-02-07 2014-08-14 Hanall Biopharma Co., Ltd. Dérivés de biguanide à substitution n1-amine cyclique-n5, leurs procédés de préparation et composition pharmaceutique les comprenant
KR102088001B1 (ko) * 2013-05-23 2020-03-12 이뮤노메트테라퓨틱스 인코포레이티드 N1-고리아민-n5-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 섬유화 예방 또는 치료용 약학 조성물
KR102192726B1 (ko) * 2013-11-04 2020-12-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
KR102144116B1 (ko) * 2013-11-25 2020-08-12 한올바이오파마주식회사 N1-고리아민-n5-치환된 바이구아나이드 화합물을 함유하는 노화에 의한 인지기능 관련 질환의 예방 또는 치료용 약학 조성물
KR102216701B1 (ko) * 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
EP3288918B1 (fr) * 2015-04-30 2021-10-20 Immunomet Therapeutics Inc. Composés de guanidine et leur utilisation
KR102253478B1 (ko) * 2015-05-13 2021-05-20 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 유도체를 유효성분으로 포함하는 교모세포종 예방 또는 치료용 의약 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114681438A (zh) * 2022-05-17 2022-07-01 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Also Published As

Publication number Publication date
US20210113497A1 (en) 2021-04-22
KR20180087189A (ko) 2018-08-01
KR102169590B1 (ko) 2020-10-26
KR20200011515A (ko) 2020-02-03
WO2018139828A1 (fr) 2018-08-02
US11826324B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
CA2747522C (fr) Antagonistes de c5ar
AU2015314830B2 (en) Cenicriviroc combination therapy for the treatment of fibrosis
KR101591701B1 (ko) 저산소증 유발 인자-1 알파의 안정화 증가 방법
ES2276194T3 (es) (-) norcisaprida opticamente pura para tratar transtornos del tracto digestivo.
ES2846003T3 (es) Procedimientos para tratar afecciones pruriginosas mediadas por receptores de histamina H-4
WO2018187503A1 (fr) Méthodes et compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3
US11826324B2 (en) Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
US20240277673A1 (en) Methods of treating behavior alterations
RU2746871C2 (ru) Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
US20220160701A1 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
CN118354766A (zh) 新型苯衍生物及其免疫抑制相关用途
CN116075302A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
AU2006334731B2 (en) Combination of triazine derivatives and insulin secretion stimulators
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
TW201238588A (en) A 5-HT4 receptor agonist as a prokinetic agent
CN102340992A (zh) 吡咯烷三重再摄取抑制剂
JP2006347935A (ja) 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬
US20240050442A1 (en) Trimeprazine derivatives and compositions comprising the same for treating a neuropsychiatric disorder
JP2009509926A (ja) リソフィリン類縁体とその使用方法
RU2799049C2 (ru) Способы лечения изменений поведения
JP2025537273A (ja) 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物との組み合わせ療法
JPWO2015115509A1 (ja) 多発性硬化症の治療剤又は予防剤
HK40047399A (en) Cenicriviroc combination therapy for the treatment of fibrosis

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMMUNOMET THERAPEUTICS INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SONG, JUNGSIK;KIM, BEOM SEOK;HA, SANG JUN;AND OTHERS;REEL/FRAME:049839/0013

Effective date: 20190711

Owner name: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SONG, JUNGSIK;KIM, BEOM SEOK;HA, SANG JUN;AND OTHERS;REEL/FRAME:049839/0013

Effective date: 20190711

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION